Navigation Links
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
Date:3/30/2009

red by the SPECT total severity score, (-256 versus +13, p=0.01). Further, patients receiving 10 or more million cells showed a trend towards improvement in ejection fraction, the percentage of blood pumped out of a ventricle with each heartbeat, (+4% versus +1%); end systolic volume (-5.7mL versus -0.1mL); and infarct size, tissue death due to loss of adequate blood supply, (-10% versus -3%) at six month follow-up. No study-related significant adverse events were reported.

"We are very encouraged that our latest findings continue to show the potential for a patient's own stem cells to reduce serious long-term complications from a heart attack," said Arshed Quyyumi, M.D., FRCP, FACC, Professor of Medicine, Cardiology, at Emory University School of Medicine and the trial's principal investigator. "This study has potentially set an important dosing threshold that offers greater protection against future down-stream adverse events, with no impact on the safety profile. Importantly, the treatment regimen is such that there is no change to our standard treatment practices. We look forward to beginning a Phase II trial."

Of the 1 million heart attacks in the U.S. each year, nearly 20% are severe enough to cause ventricular remodeling. Amorcyte's patented technologies and cGMP (current good manufacturing practices) manufacturing processes address the therapeutic and commercial challenges to post-MI stem cell treatment. Unlike other approaches, Amorcyte's technology has established cell product identity, purity, dose and potency, along with sterility and product shelf-life.

A previously published meta-analysis(1) of prior clinical trials, which included a cumulative 698 patients who received intracoronary autologous cell therapy after AMI, showed a significant improvement in ejection fraction, end systolic volumes, infarct size, reduction in subsequent MI's, and trends towards reduced deaths, admissions
'/>"/>

SOURCE Amorcyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
6. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
7. Neogen Reports Record Third Quarter
8. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
9. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
10. BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... of the most promising technologies for future quantum circuits ... instead of electrons. First, it is necessary to be ... control their direction. Researchers around the world have made ... now scientists at the Niels Bohr Institute have succeeded ... at a time and in a particular direction. The ...
(Date:8/29/2014)... Pittcon is pleased to announce that ... Matsuda, Horiba Scientific, have organized a session on nanotechnology ... JASIS , Asia’s largest analytical and scientific instruments show, ... Japan. , The four speakers in this U.S. ... Molecules to Single Cells” will present their use of ...
(Date:8/29/2014)... Three Lawrence Livermore researchers have received ... R&D Award for their research in producing ... , Shared with collaborators from the National Renewable ... Las Vegas (UNLV), the award recognizes the team ... production and corrosion processes. , These models have ...
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.541 03/2002 , , ... , , , Microorganism , ... Cell type , Bacteria, gram positive, ...
... , , , , , , , , ... Protocol No. 4308 915.533 01/2002 , , , , , ... , Microorganism , Staphylococcus aureus, ... Bacteria, gram positive, , , ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.532 01/2002 , , , ... , Microorganism , ... Cell type , Bacteria, gram negative, , ...
Cached Biology Technology:Streptococcus salivarius 2Staphylococcus aureus 2Salmonella typhimurium 2
(Date:8/28/2014)... have identified a handful of bacterial culprits that may ... and ulcerative colitis, using patients, own intestinal immune responses ... 28 in the journal Cell . , Trillions ... plays a critical role in the development and progression ... number of bacterial species affect a person,s susceptibility to ...
(Date:8/28/2014)... Clinic researcher and his collaborators have developed an online ... process of re-engineering cells for biomedical investigation. CellNet is ... to aid stem cell engineering. Details of CellNet and ... two back-to-back papers in the journal Cell . ... uses for all types of cell-based investigations and can ...
(Date:8/28/2014)... 28, 2014  Privacy Advocate and Senior Staff Attorney ... , joins the lineup of biometric and mobile commerce ... UnPlugged Executive Summit in Tampa, Florida ... announced speakers include Steven Rahman, Director, Technology and Strategy at ... Experian. The theme of this year,s event is Mobility ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... Montreal researchers has discovered that GCN2, a protein in ... long-term memory, may be a master regulator of the ... control of hippocampal synaptic plasticity and memory by the ... 25th issue of the journal Nature, provides the first ...
... motors are nanoscale engines which move along very thin rod-like ... molecular cargo within biological cells. Both motors and filaments can ... transport systems. In order to increase the flux of the ... of motors that contribute to this transport but, at the ...
... ingenious mechanism used by a particular enzyme to modify ... to designing a new kind of drug that could ... will be published in the May 6 issue of ... years that an enzyme called Dam (DNA adenine methyltransferase) ...
Cached Biology News:Montreal researchers probe the genetic basis of memory 2Motor transport in bio-nano systems 2Motor transport in bio-nano systems 3Motor transport in bio-nano systems 4Scientists take aim at virulent bacteria by decoding machinery of key control enzyme 2
... of an anodized aluminum body in a ... embedded in polymerized matrix. It is designed ... Synergy Multi-Detection Readers. This multi-functional test plate ... the need for tedious wet testing. Works ...
... The DMW143 taken from the SMZ line ... environments of production and testing. It is available ... base (FBGG) or a space-saving compact base (N2GG). ... computer, TV and a projector all at the ...
... siRNA applications, contains magnetic nanoparticles (MagTag) which ... of interest. Exploiting magnetic force the full ... towards and delivered into the target cells ... be used for adherent cells; for suspension ...
...
Biology Products: